UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

2202

7590

02/04/2011

BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747 EXAMINER

SCHULTZ, JAMES

ART UNIT PAPER NUMBER

1633

DATE MAILED: 02/04/2011

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,829	03/07/2006	Fumihiko Ishikawa	4456-0105PUS1	6864

TITLE OF INVENTION: PROCESS FOR PRODUCING HUMAN-ORIGIN IMMUNOCOMPETENT CELL

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	05/04/2011

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where n

maintenance fee notifications. CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) 2292 7590 02/04/2011				ee(s) Tran apers. Eac	ismittal. This cert ch additional pape	ificate cannot be used fo	domestic mailings of the r any other accompanying t or formal drawing, must
BIRCH STEW PO BOX 747 FALLS CHURC		I S a tr	hereby ce tates Post ddressed ansmitted	Certifical entify that this Fee al Service with st to the Mail Stop to the USPTO (5	te of Mailing or Transn (s) Transmittal is being afficient postage for first ISSUE FEE address a 71) 273-2885, on the da	nission deposited with the United class mail in an envelope above, or being facsimile te indicated below.	
							(Depositor's name)
			-				(Signature)
	_		L				(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENT	OR	ATT	ORNEY DOCKET NO.	CONFIRMATION NO.
10/560,829 TITLE OF INVENTION	03/07/2006 : PROCESS FOR PROD	OUCING HUMAN-ORIG	Fumihiko Ishikawa IN IMMUNOCOMPE	FENT CE		4456-0105PUS1	6864
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DU	E PREV	. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300		\$0	\$1810	05/04/2011
EXAM	IINER	ART UNIT	CLASS-SUBCLASS	7			
SCHULTZ	Z, JAMES	1633	435-372000	_			
"Fee Address" ind PTO/SB/47; Rev 03-0 Number is required. 3. ASSIGNEE NAME A PLEASE NOTE: Unl	ondence address (or Cha B/122) attached. ication (or "Fee Address' 12 or more recent) attach ND RESIDENCE DATA less an assignee is identi	nge of Correspondence 'Indication form ed. Use of a Customer A TO BE PRINTED ON	data will appear on the	to 3 registatively, angle firm (or agent) a ttorneys of ttorneys of ttorneys of ttorneys of type)	(having as a memund the names of ragents. If no na.	ber a 2 up to me is 3	cument has been filed for
	iate assignee category or	4l permitted)	o. Payment of Fee(s): (P A check is enclosed Payment by credit	Individual	dual Corpora t reapply any pre n PTO-2038 is at	tion or other private groueviously paid issue fee stached.	
	s SMALL ENTITY statu	is. See 37 CFR 1.27.	☐ b. Applicant is no l	onger clai	ming SMALL EN	TTITY status. See 37 CF.	R 1.27(g)(2).
interest as shown by the	records of the United Sta	tes Patent and Trademark	Coffice.	n me appi	icani; a registered	anorney or agent; or the	assignee or other party in
Authorized Signature			Date				
Typed or printed name			Registration No				
an application Confident	tiality is governed by 35 d application form to the ions for reducing this but riginia 22313-1450. DC	U.S.C. 122 and 37 CFR	1.14 This collection is	estimated	to take 12 minute	es to complete including	by the USPTO to process); gathering, preparing, and the you require to complete truent of Commerce, P.O. or Patents, P.O. Box 1450,

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/560,829	03/07/2006	Fumihiko Ishikawa	4456-0105PUS1	6864	
2292 75	590 02/04/2011		EXAM	INER	
BIRCH STEWA	RT KOLASCH & BI	SCHULTZ, JAMES			
PO BOX 747			ART UNIT	PAPER NUMBER	
FALLS CHURCH	, VA 22040-0747		1633		
			DATE MAILED: 02/04/2011		

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

	Application No.	Applicant(s)					
	10/560,829	ISHIKAWA ET AL.					
Notice of Allowability	Examiner	Art Unit					
	Lamas (Davis) Calculta Dh.D.	1000					
	James (Doug) Schultz, PhD	1633					
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not included will be mailed in due course. THIS					
1. \boxtimes This communication is responsive to $\underline{\textit{the request for continuous}}$	ued examination filed 12/14/2010.						
2. X The allowed claim(s) is/are 1.4-7.24.39.41.42 and 46-49.							
 3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents 	been received. been received in Application No						
International Bureau (PCT Rule 17.2(a)).							
* Certified copies not received:							
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.							
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give							
5. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.						
(a) I including changes required by the Notice of Draftspers	on's Patent Drawing Review (PTO-	948) attached					
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date							
(b) including changes required by the attached Examiner's Paper No./Mail Date	(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date						
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t							
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.							
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	5. ☐ Notice of Informal P 6. ☐ Interview Summary	(PTO-413),					
3. ☐ Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Dat 7. ⊠ Examiner's Amendn	re nent/Comment					
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit		ent of Reasons for Allowance					
of Biological Material	9.						
/James (Doug) Schultz, PhD/							
Primary Examiner, Art Unit 1633							

EXAMINER'S AMENDMENT

Election/Restrictions

Claims 1, 4-7, 39, 41, 42, and 46-49 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claim 24, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, is hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on 11/29/2007 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Application/Control Number: 10/560,829

Art Unit: 1633

Authorization for this examiner's amendment was given in a telephone interview with Stephanie Wardwell on January 7, 2011.

Page 3

The application has been amended as follows:

Claims 2, 20-23, 27, 34-37, 40, 43 and 44 have been canceled.

Claims 5, 7, and 24 have been rejoined.

Claim 1 has been amended to recite "A newborn NOD/SCID/IL2rg-null mouse, into which as a newborn had transplanted therein human-derived hematopoietic stem or precursor cells have been transplanted, and which is able to generate immunocompetent cells derived from said human-derived hematopoietic stem or precursor cells and and/or physiologically active substances derived from said immunocompetent cells, and wherein the immunocompetent cells comprise B cells, T cells and dendritic cells, wherein after the mouse has matured for three months: (a) bone marrow tissue extracted from the matured mouse has a ratio of human-derived hematopoietic cells to recipient-derived hematopoietic cells of between 58.8:100 and 90:100, (b) spleen tissue extracted from the matured mouse has a ratio of human-derived antibodygenerating cells to recipient-derived antibody-generating cells of between 47.1:100 and 80:100; or (c) peripheral blood extracted from the matured mouse has a ratio of human-derived antibodygenerating cells to recipient-derived antibody-generating cells of between 50.1:100 and 80:100."

In claim 4, the word "newborn" has been deleted.

In claim 5, the word "newborn" has been deleted.

In claim 6, the word "newborn" has been deleted.

In claim 7, the word "newborn" has been deleted.

Art Unit: 1633

Claim 24 has been amended to recite "A method for producing <u>human</u> immunocompetent cells, <u>which is characterized in that it</u> <u>wherein said method</u> comprises recovering said <u>human</u> immunocompetent cells from the mouse according to claim 1, or the mouse or a progeny thereof.

In claim 39, the word "newborn" has been deleted.

In claim 41, the word "newborn" has been deleted.

In claim 42, the word "newborn" has been deleted.

In claim 46, the word "newborn" has been deleted.

In claim 47, the word "newborn" has been deleted.

In claim 48, the word "newborn" has been deleted.

In claim 49, the word "newborn" has been deleted.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James (Doug) Schultz, PhD whose telephone number is (571)272-0763. The examiner can normally be reached on 8:00-4:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/560,829 Page 5

Art Unit: 1633

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/James (Doug) Schultz/ Primary Examiner, Art Unit 1633